Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) was upgraded by equities research analysts at Vetr to a “buy” rating in a research report issued on Monday.

Other equities research analysts have also recently issued reports about the stock. Cowen and Company restated a “hold” rating and issued a $430.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Roth Capital restated a “buy” rating and issued a $520.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, September 23rd. BTIG Research restated a “neutral” rating on shares of Regeneron Pharmaceuticals in a report on Thursday. Piper Jaffray Cos. set a $447.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, October 13th. Finally, Canaccord Genuity set a $450.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a report on Sunday, November 6th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $468.87.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 1.86% during midday trading on Monday, hitting $404.86. 800,750 shares of the stock were exchanged. Regeneron Pharmaceuticals has a 1-year low of $325.35 and a 1-year high of $587.38. The stock has a market capitalization of $42.44 billion, a price-to-earnings ratio of 59.07 and a beta of 1.79. The firm’s 50 day moving average is $380.96 and its 200-day moving average is $388.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, November 4th. The biopharmaceutical company reported $3.13 earnings per share for the quarter, topping analysts’ consensus estimates of $2.73 by $0.40. Regeneron Pharmaceuticals had a net margin of 16.52% and a return on equity of 21.51%. The business earned $1.22 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter last year, the firm earned $3.47 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 7.3% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $11.73 EPS for the current year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,125 shares of the business’s stock in a transaction that occurred on Monday, November 14th. The shares were sold at an average price of $450.00, for a total value of $956,250.00. Following the completion of the transaction, the director now owns 15,125 shares of the company’s stock, valued at approximately $6,806,250. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Arthur F. Ryan sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $429.34, for a total transaction of $858,680.00. Following the completion of the transaction, the director now directly owns 36,500 shares of the company’s stock, valued at approximately $15,670,910. The disclosure for this sale can be found here. 10.40% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the company. Fisher Asset Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 1.1% in the third quarter. Fisher Asset Management LLC now owns 620 shares of the biopharmaceutical company’s stock worth $249,000 after buying an additional 7 shares during the period. Wetherby Asset Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 2.3% in the second quarter. Wetherby Asset Management Inc. now owns 796 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 18 shares during the period. Waldron LP boosted its stake in shares of Regeneron Pharmaceuticals by 2.1% in the third quarter. Waldron LP now owns 856 shares of the biopharmaceutical company’s stock worth $344,000 after buying an additional 18 shares during the period. Fagan Associates Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 2.5% in the second quarter. Fagan Associates Inc. now owns 820 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 20 shares during the period. Finally, American Money Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 3.3% in the second quarter. American Money Management LLC now owns 785 shares of the biopharmaceutical company’s stock worth $274,000 after buying an additional 25 shares during the period. 68.45% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.